Su-xia Y. Luo
127 Dongming Road
Zhengzhou, China
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
Journal: Nature medicine
Published: January 22, 2025
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial.
Journal: Journal of hematology & oncology
Published: November 10, 2024
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Journal: The Lancet. Oncology
Published: August 14, 2024
First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.
Journal: Signal transduction and targeted therapy
Published: June 03, 2024
Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Journal: International journal of surgery (London, England)
Published: November 09, 2023
POU2F1/DNMT3a Pathway Participates in Neuropathic Pain by Hypermethylation-Mediated LRFN4 Downregulation Following Oxaliplatin Treatment.
Journal: Neurochemical research
Published: June 07, 2023
A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Journal: BMC medicine
Published: August 31, 2022
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Journal: BMC medicine
Published: June 09, 2022
Single-cell transcriptome sequencing reveals potential novel combination of biomarkers for antibody-based cancer therapeutics in hepatocellular carcinoma.
Journal: Frontiers in genetics
Published: May 16, 2022
PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS.
Journal: Journal of translational medicine
Published: March 02, 2022
Retraction Note: Evaluation of PAX8 expression promotes the proliferation of stomach Cancer cells.
Journal: BMC molecular and cell biology
Published: June 02, 2021
Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression.
Journal: Annals of translational medicine
Published: February 11, 2021
Last Updated: 09/26/2026